Replies to post #14461 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Silvr, the specialty pharmaceutical rep positions armed with Veeeva tools might be part of their strategy. Concordia is a Canadian company with parent Advanz Pharma headquartered in London. They likely will leverage their American manufacturing supply chain. Additionally, the only dosage form available is tablets. I wouldn't be surprised if they are working on an non-tablet form of the drug to meet the unmet need for those who have trouble swallowing tablets.

[Just the facts maam]

Silvr, my research indicates that Novitium found a way to score the 300 mg tablet and maintain the integrity of the tablet creating a 150 mg dosage. This allows them to prescribe to patients weighing 23kg or more whereas Concordia's Plaquenil and other ANDA's must leave the medication intact (no crushing or scoring).

3 DOSAGE FORMS & STRENGTHS
SOVUNA tablets are available in the following strengths:
200 mg of hydroxychloroquine sulfate: white to off-white, capsule-shaped, filmcoated tablets, debossed with "172" on one side and plain on the other side.
300 mg of hydroxychloroquine sulfate: white to off-white, functionally scored, capsule-shaped, film-coated tablets, debossed with "1" on left side of the score and
"71" on right side of the score and plain on the other side. The scoring allows the tablet to be divided into two equal halves containing 150 mg each.

From what I can tell all the other tablets have to be taken intact (no scoring or crushing). It gives ANIP dose of 150 mg, 200mg, 300mg, 350 mg, 400 mg,450 mg etc.. while the others with tablets that can not be scored are restricted to appear to be restricted to doses increasing in 100mg increments.

Add the fact that ANIP supply chain is US based this could be a very big revenue generator.

Now when will they announce it?